A serious and longstanding quality of care problem in nursing homes is the inappropriate use of antipsychotic drugs with residents who have dementia. A decade ago, the HHS Office of Inspector General (OIG) reported that 83% of claims for … [Read more...] about HHS Inspector General Finds CMS Data Understates Antipsychotic Drug Use in Nursing Homes
Search Results for: antipsychotics
Transition Memorandum for Biden Administration Department of Health & Human Services (HHS)
December 2020 Links to detailed sections below I. Introduction II. Executive Summary: Administrative Measures III. Medicare Platform: Legislative Agenda IV. Administrative Action: Full Recommendations Strengthen Protections for Nursing … [Read more...] about Transition Memorandum for Biden Administration Department of Health & Human Services (HHS)
CMA Alert – October 17, 2019
Center for Medicare Advocacy Board President Judith Feder Testifies at Drug Pricing Hearing Administration’s “Public Charge” Rule [Temporarily?] Blocked Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing … [Read more...] about CMA Alert – October 17, 2019
Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing Home Residents to Pay Over $115 Million
Background When the Centers for Medicare & Medicaid Services (CMS) launched a national campaign to reduce the off-label prescribing of antipsychotic drugs for nursing home residents in 2012, Avanir Pharmaceuticals directed its sales force to … [Read more...] about Drug Company Sued Over Kickbacks for Off-Label Marketing of Psychotropic Drug for Nursing Home Residents to Pay Over $115 Million
Center Comments on Proposed Rule to Revise Nursing Home Requirements of Participation
September 15, 2019 Administrator Seema Verma Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-3347-P P.O. Box 8010 Baltimore, MD 21244-1850 Re: CMS-3374-P; Federal Register, Vol. 84, No. … [Read more...] about Center Comments on Proposed Rule to Revise Nursing Home Requirements of Participation
CMA Alert – August 29, 2019
Advocates Issue Joint Letter Raising Alarms about New Medicare Plan Finder and Revisions to MA and Part D Marketing Guidelines CMS Proposed Medicare Home Health Rules Raise Concerns for Access to Care – Comments due September 9, 2019 Stop … [Read more...] about CMA Alert – August 29, 2019
Stop Drugging Nursing Home Residents Without their Written Consent
Background. Nursing homes administer antipsychotic drugs to approximately 20 percent of residents nationwide. Sadly, and too often, nursing homes use these drugs as a way of chemically restraining residents exhibiting the behavioral symptoms of … [Read more...] about Stop Drugging Nursing Home Residents Without their Written Consent
CMA Alert – January 31, 2019
#MedicarePlatform - Improve and Expand Medicare: Long-Term Services and Supports (LTSS) Center Submits Comments on Proposed Medicare Prescription Drug Rule Congressional Hearings Explore Rising Prescription Drug Costs Medicare’s New … [Read more...] about CMA Alert – January 31, 2019
Center Submits Comments on Proposed Medicare Prescription Drug Rule
The Center for Medicare Advocacy recently submitted comments to a Notice of Proposed Rulemaking issued by the Centers for Medicare & Medicaid Services (CMS) entitled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce … [Read more...] about Center Submits Comments on Proposed Medicare Prescription Drug Rule
Center Comments on “Modernizing Part D and Medicare Advantage”
January 25, 2018 Submitted via www.regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P Re: CMS-4180-P: Modernizing Part D and Medicare Advantage to Lower Drug Prices … [Read more...] about Center Comments on “Modernizing Part D and Medicare Advantage”